Trials / Completed
CompletedNCT04436029
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Descartes 11 | Car T-cells |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2022-02-18
- Completion
- 2022-04-09
- First posted
- 2020-06-17
- Last updated
- 2024-12-03
- Results posted
- 2024-12-03
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04436029. Inclusion in this directory is not an endorsement.